* Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-...
* Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitori...
* Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables mon...
* Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Of...
* Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diag...
- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University,Singap...
* Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzh...
* Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side...
* Highlight brain imaging analysis solutions, including 'Neurophet AQUA AD', which monitors side ...
* Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imagi...
- Showcased core technology and products for personalized tDCS at the conference inKobe, Japan - P...
* Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance * Introduces 'Neuro...
* New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensi...
- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology a...
* Neurophet enters into a strategic agreement with LADO to distribute Neurophet SCALE PET * Imp...
- Invited Neurophet's scientific advisor Stephen Salloway, professor of Neurology at Brown Medical ...
- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global ...
- Neurophet accelerates global expansion for research and partnership in AI-driven brain image anal...
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated...
- Presents a poster identifying tDCS effects for patients with AD and cognitively normal people - ...
